|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||301.30 - 306.70|
|52-week range||220.20 - 335.33|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||48.33|
|Forward dividend & yield||3.92 (1.30%)|
|Ex-dividend date||12 Aug 2022|
|1y target est||N/A|
Eli Lilly and Company (NYSE: LLY) announced today the availability of a new, citrate-free formulation of Taltz® (ixekizumab) injection 80 mg/mL. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formulation. The new Taltz formulation significantly reduced injection site pain experienced by some people immediately following injection as shown by an 86% decrease in a visual analog scale (VAS) o
Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties.
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2022.